YMYuko Minami

Yuko Minami

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuko Minami has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Masayuki Noguchi

    Department of Pathology Faculty of Medicine University of Tsukuba Ibaraki Japan

    6 shared publications
  • Tatsuo Iijima

    Department of Pathology Ibaraki Prefectural Central Hospital Ibaraki Japan

    5 shared publications
  • Yukio Morishita

    4 shared publications
  • Chigusa Okubo

    Department of Pathology, Institute of Basic Medical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan

    2 shared publications
  • Yukinori Inadome

    Department of Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan

    2 shared publications
  • Yukio Sato

    Department of Thoracic Surgery, Faculty of Medicine, University of Tsukuba , Tsukuba, Ibaraki 305‑8575

    2 shared publications

Latest Publications

  • Open Access

    ECT2 amplification and overexpression as a new prognostic biomarker for early‐stage lung adenocarcinoma

    by Yoshihiko Murata, Yuko Minami, Reika Iwakawa, Jun Yokota, Shingo Usui, Koji Tsuta, Kouya Shiraishi, Shingo Sakashita, Kaishi Satomi, Tatsuo Iijima, et al.

    Genetic abnormality in early‐stage lung adenocarcinoma was examined to search for new prognostic biomarkers. Six in situ lung adenocarcinomas and nine small but invasive adenocarcinomas were examined by array‐comparative genomic hybridization, and candidate genes of interest were screened. To examine gene abnormalities, 83 cases of various types of lung carcinoma were examined by quantitative real‐time genomic PCR and immunohistochemistry. The results were then verified using another set of early‐stage adenocarcinomas. Array‐comparative genomic hybridization indicated frequent amplification at chromosome 3q26. Of the seven genes located in this region, we focused on the epithelial cell transforming sequence 2 (ECT2) oncogene, as ECT2 amplification was detected only in invasive adenocarcinoma, and not in in situ carcinoma. Quantitative PCR and immunohistochemistry analyses also detected overexpression of ECT2 in invasive adenocarcinoma, and this was correlated with both the Ki‐67 labeling index and mitotic index. In addition, it was associated with disease‐free survival and overall survival of patients with lung adenocarcinoma. These results were verified using another set of early‐stage adenocarcinomas resected at another hospital. Abnormality of the ECT2 gene occurs at a relatively early stage of lung adenocarcinogenesis and would be applicable as a new biomarker for prognostication of patients with lung adenocarcinoma.


  • Open Access

    A Case of Perforation in the Small Intestine Due to Metastasis from Lung Adenocarcinoma with a Rhabdoid Phenotype

    by Naohiro Kobayashi, Masatoshi Yamaoka, Yukinobu Goto, Yukio Sato, Yuko Minami, Masayuki Noguchi

    背景.肺癌の小腸転移は2.8~5.7%と頻度が低く,大細胞癌・未分化癌に多い.一方,ラブドイド腫瘍は1999年のWHO肺胸膜腫瘍の組織型分類において,大細胞癌の特殊型に加えられている.その予後は不良で,時に小腸転移が認められる.今回,我々はラブドイド形質を伴った肺腺癌で小腸転移をきたした1例を経験したので報告する.症例.64歳,女性.特発性間質性肺炎の経過観察中に胸部異常陰影を指摘された.気管支鏡下細胞診でclass IVの結果で,左肺腺癌を疑い,左肺下葉切除術を行った.病理組織診断は肺腺癌で,腫瘍全体の8%にラブドイド形質を伴った腫瘍細胞が混在していた.術後5カ月目に小腸穿孔を発症し,緊急手術を行った.病理組織診断はラブドイド形質を伴った腫瘍細胞による肺癌の小腸転移であった.術後化学療法を施行したが,再度小腸転移による穿孔を発症し,敗血症で死亡した.結論.ラブドイド形質を伴う肺癌は予後不良で,小腸転移をきたす可能性を含めた注意深い経過観察が必要である.

    • 1 October 2006
      • Vol. 1  (8) , 780-6

    Analysis of differentially expressed genes in neuroendocrine carcinomas of the lung.

    by Chigusa Okubo, Yuko Minami, Ryota Tanaka, Teruhito Uchihara, Yoichi Anami, Shuichiroh Furuya, Yukio Morishita, Tatsuo Iijima, Masayuki Noguchi

    Large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) show considerable differences in their histology but share neuroendocrine (NE) characteristics and also genetic and/or expression patterns. We used the subtractive expression method to identify differences in gene expression that would allow discrimination between these two types of NE lung carcinoma. Eight cDNA fragments were transcribed at a higher level in LCNEC compared with SCLC, and these corresponded to five mitochondrial genes, two ribosomal genes, and one fetal regulation factor, neuronatin (NNAT). Immunohistochemically, NNAT protein was detected in 43% (6/14) of LCNECs but in only 8% (1/13) of SCLCs (p < 0.05). Positive staining for NNAT was observed in areas that did not show the NE morphology, such as palisading and rosettes. The present results suggest that NNAT has the potential to be used as a differential maker between LCNEC and SCLC.


  • Phenotypic characteristics of mouse lung adenoma induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone

    by Chigusa Okubo, Yukio Morishita, Yuko Minami, Tadashi Ishiyama, Junko Kano, Tatsuo Iijima, Masayuki Noguchi


  • Open Access

    Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma

    by Ryota Tanaka, Daye Wang, Yukio Morishita, Yukinori Inadome, Yuko Minami, Tatsuo Iijima, Shimao Fukai, Tomoyuki Goya, Masayuki Noguchi

    BACKGROUND Stepwise progression of peripheral‐type lung adenocarcinoma was characterized morphologically and was related to prognosis. Expression of the tumor suppressor gene p16 in pulmonary adenocarcinoma decreased, mainly as a result of aberrant methylation of the CpG islands of the promoter region. METHODS Aberrant methylation status of the p16 promoter region, the expression of its product, and loss of heterozygosity (LOH) on 9p21 were examined in surgically resected lung specimens from 57 patients (28 males and 29 females) with peripheral‐type lung adenocarcinoma measuring ≤ 2 cm in diameter. RESULTS Aberrant methylation of the p16 promoter region, negative p16 protein expression, and LOH of the 9p21 region were detected in 40.4%, 50.9%, and 40.4% of tumor samples, respectively. The alterations of the p16 gene were associated with poor prognosis, and in particular the prognosis of patients with aberrant p16 methylation was significantly worse than that of patients without aberrant methylation. These alterations also were associated with morphologic classification into bronchioloalveolar carcinoma (BAC) and non‐BAC adenocarcinoma. Both aberrant methylation and LOH of 9p21 were associated with negative protein expression, but the former was correlated more closely with loss of function than was the latter. Cases with both alterations were completely negative for expression of the p16 gene product. CONCLUSIONS Aberrant methylation of the promoter region of the p16 gene and loss of expression of its product were in accord with the multistep progression of peripheral‐type lung adenocarcinoma, and these alterations were associated closely with poor prognosis of the disease. Cancer 2005. © 2004 American Cancer Society.


  • MMP-2 activation and stepwise progression of pulmonary adenocarcinoma: Analysis of MMP-2 and MMP-9 with gelatin zymography

    by Tatsuo Iijima, Yuko Minami, Naoko Nakamura, Masataka Onizuka, Yukio Morishita, Yukinori Inadome, Masayuki Noguchi

    Small pulmonary adenocarcinomas can be classified on the basis of their histological characteristics and prognosis, and when classified as such, the prognosis of replacing-type adenocarcinoma with active fibroblast proliferation is significantly worse than adenocarcinoma without fibroblast proliferation. In order to clarify the biological mechanisms of the key to the morphological changes associated with active fibroblast proliferation, we examined the activities of matrix metalloproteinase (MMP)-2 and MMP-9, which are important enzymes in the stromal invasion by cancers. The active MMP-2 and MMP-9 content of 40 pulmonary adenocarcinomas that were less than 20 mm in diameter was measured by the gelatin zymography method. The quantity of active MMP-2 in the pulmonary adenocarcinomas with active fibroblast proliferation was higher than in the pulmonary adenocarcinomas without proliferation (P < 0.001), but there were no correlations between the histological features and the activation of MMP-9. The presence of active fibroblast proliferation in small pulmonary adenocarcinomas suggests that the cancer cells have acquired the ability to invade through the action of active MMP-2, and this is thought to be one of the reasons for the worse prognosis of pulmonary adenocarcinoma with active fibroblast proliferation.


  • Open Access

    High Resolution CT for Localization of Early Hilar Lung Carcinoma.

    by Yuko Minami, Shigemi Ishikawa, Yukihisa Saida, Motomasa Kajitani, Masayuki Noguchi, Tatsuo Yamamoto, Yukio Sato, Masataka Onizuka, Yuzuru Sakakibara

    目的. 胸部単純X線写真無所見肺門部肺癌の局在診断における高分解能CT (以下HRCT) の有用性を検討することを目的とした. 方法. 気管支鏡検査に先行して肺門部のHRCTを施行し読影した. 気管支病変の診断は白色光及び蛍光気管支鏡で観察し, 最終診断は内視鏡所見及び生検によった. 対象. 胸部単純X線写真上所見を認めず, 喀痰細胞診あるいは血痰から肺門部肺癌が疑われる19症例を対象とした. 結果. 19例中8例で肺門部扁平上皮肺癌が証明され, 11例は非悪性症例であった. HRCTで19例中13例に19部位の肺門部気管支に異常所見を認めた. このうち9部位が気管支鏡でも有所見であった. 悪性病変は全部で8病変であり, CTで描出できなかったのは1病変のみでそれは上皮内癌であった. 気管支鏡での有所見は全部で20部位であったが, 上記の上皮内癌を含む4部位 (20%) がCTで捉えられなかった. 結論. 胸部X線写真無所見肺門部肺癌の局在診断において, HRCTで気管支鏡有所見部位の80%を捉えることができた. 癌と診断された8病変中7病変 (87.5%) を指摘することが可能であった. 有用な補助診断法の1つとなり得ると考えられた.